Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with Coronavirus Disease 19 (COVID-19) from the perspective of National Health Service England
Abstract:

Purpose: Estimate the clinical and economic benefits of lenzilumab plus standard of care (SOC) compared with SOC alone in the treatment of hospitalized COVID-19 patients from the National Health Service (NHS) England perspective.

Methods: A cost calculator was developed to estimate the clinical benefits and costs of adding lenzilumab to SOC in newly hospitalized COVID-19 patients over 28 days. The LIVE-AIR trial results informed the clinical inputs: failure to achieve survival without ventilation (SWOV), mortality, time to recovery, intensive care unit (ICU) admission, and invasive mechanical ventilation (IMV) use. Base case costs included drug acquisition and administration for lenzilumab and remdesivir and hospital resource costs based on level of care required. Clinical and economic benefits per weekly cohort of newly hospitalized patients were also estimated.

Results: In all populations examined, specified clinical outcomes were improved with lenzilumab plus SOC over SOC treatment alone. In a base case population aged <85 years with C-reactive protein (CRP) <150 mg/L, with or without remdesivir, adding lenzilumab to SOC was estimated to result in per-patient cost savings of £1,162. In a weekly cohort of 4,754 newly hospitalized patients, addition of lenzilumab to SOC could result in 599 IMV uses avoided, 352 additional lives saved, and over £5.5 million in cost savings. Scenario results for per-patient cost savings included: 1) aged <85 years, CRP <150 mg/L, and receiving remdesivir (£3,127); 2) Black patients with CRP <150 mg/L (£9,977); and 3) Black patients from the full population (£2,369). Conversely, in the full mITT population, results estimated additional cost of £4,005 per patient.

Conclusion: Findings support clinical benefits for SWOV, mortality, time to recovery, time in ICU, time on IMV, and ventilator use, and an economic benefit from the NHS England perspective when adding lenzilumab to SOC for hospitalized COVID-19 patients.
Introduction

The societal and economic impacts of the Coronavirus Disease 2019 (COVID-19) pandemic have been substantial in the United Kingdom (UK) and worldwide. As of January 25, 2022, the World Health Organization has reported over 352 million COVID-19 cases and over 5.6 million deaths globally. As of January 25, 2022, over 16 million people in the UK have tested positive for COVID-19, with 685,624 patients being admitted to hospitals and 176,813 deaths with COVID-19 on the death certificate. A study of 20,133 patients hospitalized with COVID-19 in the UK found that 17% of hospitalized patients required admission to the intensive care unit (ICU) and of these patients, 32% died. Moreover, 10% of patients hospitalized for COVID-19 required invasive mechanical ventilation (IMV), with 37% of these patients dying. Despite approximately 83.9% and 64.3% of the UK population aged ≥12 years having received two and three vaccination doses, respectively, as of January 25, 2022, the need for effective treatments for hospitalized COVID-19 patients remains, particularly with the continued emergence of new COVID-19 variants, including the Omicron variant in November 2021. Whilst there is evidence of vaccine effectiveness against symptomatic infection and hospitalization, a highly transmissible variant such as Omicron can lead to an increase in hospital admissions. As of January 23, 2022, the number of COVID-19 patients to admitted UK hospitals in the past 30 days more than doubled, relative to the previous 30-day period. As new variants continue to emerge, there remains an urgent unmet need for effective therapies for patients who are hospitalized with COVID-19 to prevent IMV and/or death. There is a substantial economic burden associated with the treatment of COVID-19 in terms of overall healthcare costs. From the hospital perspective, providing care to patients with COVID-19 in the UK is associated with average per-patient daily costs ranging from a low of 883 euros (EUR) for patients who do not require ICU admission or IMV to a high of 3,183 EUR for patients who require both ICU admission and IMV (as reported in 2020). Given that hospitalized
patients with COVID-19, especially those requiring IMV, have more detrimental health outcomes and a higher economic burden, safe and effective treatment options that provide good value for money represent a significant unmet need. An increased risk of IMV and death in COVID-19 patients has been linked to a process known as immune-mediated hyperinflammation. This process is largely mediated by granulocyte-macrophage colony-stimulating factor (GM-CSF), a protein that is produced locally in inflamed tissue in response to COVID-19 infection. Activated GM-CSF functions to activate and mobilize myeloid cells, resulting in the excessive production of downstream pro-inflammatory cytokines, including interleukin-6 (IL-6). C-reactive protein (CRP) is an acute phase reactant produced by the liver largely in response to IL-6, and CRP levels serve as a reliable surrogate for IL-6 bioactivity. Lung tissue injury, disease severity, and ICU admission of patients with COVID-19 have been directly correlated with both GM-CSF levels and CRP levels at the time of hospital admission. Further, neutralization of GM-CSF is expected to prevent or reduce the severity and sequelae of immune-mediated hyperinflammation. As such, GM-CSF has been identified as an important therapeutic target of COVID-19. Lenzilumab is a novel Humaneered anti-human GM-CSF monoclonal antibody that directly binds GM-CSF, thereby preventing its downstream signaling. This mechanism of action of lenzilumab renders it a promising new treatment option as its efficacy is likely unaffected by new COVID-19 variants. LIVE-AIR (NCT04351152) was a Phase 3, prospective, randomized, multicentered, double-blind, placebo-controlled clinical trial that evaluated the efficacy and safety of lenzilumab or placebo (in addition to institutional standard of care [SOC] in both treatment groups) in hospitalized participants with COVID-19 pneumonia. Patients must have been hospitalized with an oxygen saturation (SpO₂) ≤94% on room air or required supplemental oxygen but had not progressed to IMV. Results from the LIVE-AIR trial showed that lenzilumab
plus SOC significantly improved the likelihood of achieving survival without ventilation (SWOV)\(^a\) (sometimes referred to as ventilator-free survival) by day 28 compared with placebo plus SOC.\(^23\) Additional analyses revealed that lenzilumab plus SOC had greater efficacy in patients aged <85 years with CRP levels <150 mg/L, overall and exclusively in patients receiving remdesivir, compared with placebo plus SOC, as measured by SWOV.\(^{39,40}\) As previously mentioned, CRP levels are elevated in the process of immune-mediated hyperinflammation and have been linked to poor clinical outcomes among patients with severe COVID-19.\(^{23,34,35,40}\) Therefore, evidence from the LIVE-AIR trial suggest that lenzilumab may have greater efficacy when administered as an early intervention in hospitalized patients with COVID-19.

Results from an exploratory analysis of the LIVE-AIR trial also suggested that Black and African American patients with baseline level CRP <150 mg/L may exhibit the greatest response to lenzilumab, with a nearly 9-fold increase in the likelihood of SWOV.\(^{41}\) This is notable as the Office of National Statistics (ONS) reported that the COVID-19 death rate was higher for Black African (2.16 greater for males and 1.62 greater for females) and Black Caribbean (1.69 greater for males and 1.35 greater for females) populations in the UK compared to their White British counterparts, during the second wave of the COVID-19 pandemic (September 12, 2020 to March 31, 2021).\(^{42}\) The hyper-vulnerability in this population can be largely attributed to low vaccination rates, as a recent UK-wide survey identified Black or Black British respondents as having the highest rate of vaccine hesitancy (71.8%).\(^{43}\) Further, the Black population, on average, has a higher incidence and prevalence of chronic illness (eg, diabetes, hypertension, obesity) and lower socioeconomic status, both of which result in higher risk of infection, hospitalization, and death.\(^{43,44}\)

\(^a\) SWOV is a robust composite endpoint used in many of the recent COVID-19 studies that is less prone to favor treatments with discordant effects on survival and days free of ventilation while avoiding the need for sample sizes approaching those of mortality trials to enable timely availability of study results.
Although clinical evidence supports that lenzilumab effectively improves the likelihood of SWOV in hospitalized patients with COVID-19, its overall clinical and economic value from the National Health Service (NHS) England perspective has not been previously characterized. The objective of this study was to report the clinical benefits of the LIVE-AIR trial in a meaningful way to the NHS England perspective, and to estimate the per-patient and population-level costs using the clinical trial data to demonstrate the economic benefit of lenzilumab plus SOC compared with SOC alone in the treatment of hospitalized COVID-19 patients. This analysis was conducted ex ante (ie, before regulatory approval of lenzilumab).

Methods

Calculator Structure

We previously developed a Microsoft® Excel-based cost calculator to estimate the clinical benefits and per-patient costs of lenzilumab plus SOC versus SOC alone for newly hospitalized patients with COVID-19 pneumonia from a United States (US) hospital perspective. This calculator was adapted to represent a UK healthcare payer perspective, specifically that of NHS England. A 28-day model time horizon for the index COVID-19 hospitalization was selected to align with data censoring for the LIVE-AIR trial (28 days following enrollment). A patient-level analysis was conducted to estimate the clinical benefits and per-patient costs for an average of newly hospitalized patients with COVID-19 pneumonia in England. A cohort-level analysis was also conducted considering all newly hospitalized patients in a 1-week period. The calculator structure is presented in Figure 1.

Target Population

Patient eligibility for the calculator was based on inclusion criteria for the LIVE-AIR trial. In brief, eligible patients were newly hospitalized with COVID-19 pneumonia, with SpO₂ ≤94% on room air and/or requiring supplemental oxygen, but not on IMV. Further analyses of LIVE-AIR trial data suggested that patients aged <85 years with CRP <150 mg/L particularly benefited from
lenzilumab, and this population was selected for the base case.\textsuperscript{39,40} Since the ongoing and fully
enrolled ACTIV-5/BET-B trial, which aims to further elucidate the efficacy of lenzilumab in
COVID-19 in patients aged <85 years with CRP <150 mg/L and receiving remdesivir, this
population was explored in a scenario analysis (scenario #1).\textsuperscript{46,47} This population receiving
remdesivir was not selected for the base case given the lower use of remdesivir in the UK
(16.7\textsuperscript{48} to 48.4\textsuperscript{49}) compared with that observed in the LIVE-AIR trial (72.4\%) conducted
primarily in the US.\textsuperscript{23} Scenario analyses were also conducted in the full LIVE-AIR modified
intent-to-treat (mITT) population\textsuperscript{b} (scenario #2), in Black patients with CRP <150 mg/L (with or
without remdesivir) (scenario #3), and in Black patients from the full mITT population (scenario
#4). Data for the mITT population of the LIVE-AIR trial, the pre-specified primary analysis
population, were used for all analyses.\textsuperscript{50}

\textbf{Cohort Size Estimates}

Weekly cohort sizes for the base case and scenario analyses were calculated using recent case
count reports from UK government sources, the LIVE-AIR trial, and a physician survey. The
physician survey was conducted between August 13 to 25, 2021 with 82 medically qualified and
practicing pulmonary medicine physicians, infectious disease specialists, and intensive care
specialists in the UK.\textsuperscript{49} All physicians were consultants and senior non-consultant hospital doctors
and all had treated patients with COVID-19.\textsuperscript{49} In a 1-week period from January 17 to January 23,
2022, there were an estimated 11,343 newly hospitalized COVID-19 patients in England.\textsuperscript{13} Based
on the physician survey, 60.1\% of hospitalized patients have SpO\textsubscript{2} less than 94\%,\textsuperscript{49} and would be
eligible for treatment in the base case and scenario analyses. To calculate all subgroups with
CRP <150 mg/L (base case, scenario #1 and #3), it was assumed that 77.9\% of the population

\textsuperscript{b} The mITT population was the analysis set used for the primary analysis of efficacy, defined as
all randomized subjects who received at least one dose of study drug under the documented
supervision of the principal investigator or sub-investigator and excluding sites that experienced
documented limitations to access of basic supportive care for COVID-19.
with SpO₂ <94% had CRP <150 mg/L, as observed in the LIVE-AIR trial population. For subgroups restricted to age <85 years (base case, scenario #1), it was assumed that 89.5% of the hospitalized population was <85 years according to NHS data for hospital admissions in 2020-2021. The subgroup receiving remdesivir (scenario #1) was calculated using data from the physician survey for the percentage of patients with CRP <150 mg/L who are treated with remdesivir, which was estimated at 37.7%. Finally, for the scenarios in the Black population (scenario #3 and #4) it was assumed that 3.8% of patients were Black according to NHS hospital admissions in 2020-2021. This resulted in a weekly cohort size of eligible patients of 4,754 for the base case and cohort sizes of 1,792, 6,817, 200, and 256 patients for scenarios #1 through 4, respectively. The calculations for the cohort size estimates are illustrate in Figure 2.

**Treatment Efficacy**

Calculator inputs for treatment efficacy of lenzilumab plus SOC versus SOC alone were obtained from the LIVE-AIR trial. Treatment efficacy inputs for the base case and scenario analyses included failure to achieve SWOV, mortality, time to recovery, time in ICU, and time on IMV, as previously reported in the US hospital perspective analysis by Kilcoyne and colleagues (2022). Mean time to recovery was used as a proxy for a patient’s length of stay. The values used for the treatment efficacy inputs are provided in the Supplementary Appendix.

**Clinical Outcomes**

Using the treatment efficacy data from the LIVE-AIR trial, clinical outcomes were then reported in a manner relevant to healthcare payers. This included number needed to treat (NNT) for one

\[^{c}\] Time to recovery was a pre-specified secondary outcome of the LIVE-AIR trial and was defined as the first day on which a patient was discharged or ready for discharge by satisfying one of the following 3 categories from the 8-point ordinal scale: hospitalized, not requiring supplemental oxygen, no longer requiring ongoing medical care; not hospitalized, limitation on activities and/or requiring home oxygen; not hospitalized, no limitations on activities.
patient to achieve SWOV, reduction in IMV use, NNT for one life saved, and the number of bed
days, ICU days, and IMV days saved.

Cost Calculator

Base case costs included drug acquisition and administration for lenzilumab and remdesivir and
hospital resource costs based on the level of care required. It was important to consider the
proportion of patients in each treatment arm expected to receive remdesivir given the difference
in the use in UK clinical practice compared with that observed in the LIVE-AIR trial. Additional
details on the assumptions and calculations for remdesivir use can be found in the
Supplementary Appendix.

Adverse event (AE) management costs were not considered because minimal
differences in the incidence of grade ≥3 AEs were observed in the LIVE-AIR trial (under 3%
difference for all individual AEs) and the overall incidence of grade ≥3 AEs was lower in the
lenzilumab plus SOC arm compared to the placebo plus SOC treatment arm (26.7% versus
32.7% for the safety populations, respectively).\textsuperscript{23}

Drug Acquisition Costs

A targeted literature review was conducted to support costing parameterization for the calculator.
All costs were reported in 2021 pound sterling (GBP), with adjustments for inflation made as
needed based on the consumer price inflation (CPI) time series (CPI INDEX 06: HEALTH) from
the ONS.\textsuperscript{52} It was assumed that 72.1\% of lenzilumab plus SOC patients received concomitant
remdesivir in the base case and all scenario analyses (excluding scenario #1), in alignment with
the actual use in the LIVE-AIR trial.\textsuperscript{23} In the base case analysis and Scenario #3 (Black with CRP
<150 mg/L), remdesivir use was estimated at 37.7\% for patients who received SOC alone, based
on the physician survey for treatment of patients with CRP <150 mg/L.\textsuperscript{49} As scenario #1
considered patients aged <85 years with CRP <150 mg/L and receiving remdesivir, remdesivir
use was set at 100\% for both the lenzilumab plus SOC and SOC alone arms. For scenarios #2
(full mITT population) and #4 (Black patients from the full mITT population), 48.4\% of patients in
the SOC alone arm were assumed to receive remdesivir, based on the physician survey for treatment of patients with SpO\textsubscript{2} ≤ 94\%, regardless of CRP level.\textsuperscript{49} Additional details on the assumptions and calculations for remdesivir use can be found in the Supplementary Appendix.

The drug acquisition cost for lenzilumab was £7,300 per patient for the entire treatment course, based on the official UK list price;\textsuperscript{53} this was calculated as a cost of £406 per 100 mg vial and a dosing regimen of three 600 mg doses, each administered by a 1-hour intravenous infusion 8 hours apart, for a total of 1800 mg per patient.\textsuperscript{23} The total drug acquisition cost for remdesivir was £2,040; this was calculated using a cost of £340 per 100 mg vial\textsuperscript{54} and assuming a course of 6 vials based on the recommended 200 mg loading dose on day 1 and 100 mg maintenance doses on days 2-5.\textsuperscript{55}

**Drug Administration Costs**

Lenzilumab administration costs were assumed to be £33.92 per intravenous infusion, for a total administration cost of £101.76. This cost was calculated based on the pharmacy labor cost associated with the aseptic preparation and administration of a monoclonal antibody.\textsuperscript{56,57} Aseptic technique was included for lenzilumab as its preparation requires the compounding of six 100 mg vials and is therefore considered a medium-risk for contamination.\textsuperscript{58} It was assumed that remdesivir administration costs were £14.75 per infusion, for a total administration cost of £73.75. This cost was calculated based on the pharmacy labor cost associated with administration of a monoclonal antibody, with no aseptic preparation.\textsuperscript{57} It was assumed that additional time for aseptic compounding was not needed for remdesivir as its preparation includes combination of no more than two drug vials and thus is considered a low-risk for contamination.\textsuperscript{58}

Nursing administration costs for intravenous infusions, as well as drug and administration costs for other SOC drugs, including corticosteroids, were assumed to be captured in the hospital resource costs. Costs associated with other SOC drugs were not included as separate inputs in the calculator because it was assumed that lenzilumab would not impact the utilization or cost of background therapies other than remdesivir; this assumption was supported by balanced
corticosteroid use in both arms of the LIVE-AIR trial. Additional details on calculations for administration costs can be found in the Supplementary Appendix.

**Hospital Resource Use and Costs**

In alignment with the US hospital perspective model, patients were divided into four levels of care required during their hospital stay: no ICU and no IMV, ICU but no IMV, IMV but no ICU, and both ICU and IMV. Daily hospital resource cost inputs were obtained from a study by Czernichow and colleagues (2020), which reported mean cost per bed type per day in the UK. A cost corresponding to the “IMV but no ICU” level of care was not provided in the study, so it was assumed to be equivalent to the difference between the “both ICU and IMV” and “ICU but no IMV” groups, added to the base hospitalization cost (ie, “no ICU or IMV”). Czernichow and colleagues reported all costs in their study in EUR, using an exchange rate of 1.11 EUR to 1 GBP; these costs were reconverted using that exchange rate and then inflated from 2020 to 2021 values to provide the following hospital costs per day: £876 (no ICU, no IMV), £1,978 (ICU, but no IMV), £2,043 (IMV, but no ICU), and £3,145 (both ICU and IMV). It was assumed that these daily costs incorporated all costs associated with SOC in the UK, including any corticosteroid use.

Inputs for hospital resource use were informed by data from the LIVE-AIR trial and included patient distributions and time to recovery for each level of care, as previously reported by Kilcoyne and colleagues (2022). Costs and resource use for each level of care are provided in the Supplementary Appendix.

Hospital resource costs per patient were calculated as a weighted average based on the four levels of care required. First, the average time to recovery for each of the four levels of care was multiplied by the corresponding daily hospital resource cost to obtain the average total hospital resource cost for each level of care. Next, the weighted average cost per patient was calculated as the sum product of average total hospital resource costs for each level of care and the corresponding proportion of patients requiring each level of care. These calculations were performed independently for the lenzilumab plus SOC and SOC alone arms to obtain separate...
weighted average hospital resource costs for the two treatment options. Additional details on hospital resource cost calculations are provided in the Supplementary Appendix.

**Total Costs and Economic Impact**

Total costs were calculated for each treatment arm; this included drug costs, administration costs, and hospital resource costs. The difference in total costs between the two arms was then calculated to estimate the average cost per patient treated with lenzilumab plus SOC instead of SOC alone. To obtain results for the weekly cohort, the average cost per patient was multiplied by the number of newly hospitalized patients eligible for treatment in a 1-week period.

**Scenario Analyses**

The base case analysis included patients aged <85 years with CRP <150 mg/L. Four scenario analyses were conducted to examine the per-patient cost of adding lenzilumab to SOC in other patient populations. Scenario analysis #1 included a narrower population by only including base case patients who received concomitant remdesivir. Scenario analysis #2 examined a broader population and included the full LIVE-AIR mITT population. The other two scenario analyses focused on Black patients, a population that is disproportionally affected by COVID-19. Scenario analysis #3 included Black patients with CRP <150 mg/L, with or without remdesivir, whereas scenario analysis #4 included Black patients from the full mITT population.

**Sensitivity Analyses**

Sensitivity analyses were conducted to determine the key drivers of the cost calculator. The following calculator inputs were included for sensitivity analyses: daily hospital resource costs, patient distributions in each level of care (lenzilumab plus SOC arm only), lenzilumab drug costs, and remdesivir use (SOC alone arm only). Daily hospital resource cost inputs were adjusted by ±25% and each level of care was adjusted simultaneously. Given that in the cost calculator, the total hospital resource cost at each level of care is the product of the respective daily hospital resource cost and the time to recovery, the adjustment of daily hospital resource costs by ±25%
has the same impact as adjusting time to recovery by ±25%; therefore, additional sensitivity analyses for time to recovery were not conducted. For patient distributions, the proportion of patients requiring both ICU and IMV was adjusted ±25% first and then the three other levels of care were reweighted, maintaining the proportionality between the levels of care prior to adjustment. The decision to use the ICU and IMV group for adjustment in the sensitivity analysis was based on the assumption that this group was the largest driver of costs in the model, as a result of the increased cost of care per day and the longer length of stay. The input for lenzilumab drug cost was adjusted by +10% and −25%. The variability in the upper estimate (+10% price increase) was selected to be smaller than the lower estimate (−25% price reduction) as the drug cost used in the base case analysis of the cost calculator represents the official UK list price of lenzilumab and, therefore, an increase of more than 10% of the list price in the UK is not anticipated. Lastly, for remdesivir use in the SOC arm, 16.7% was used as the low estimate based on a study by Arch and colleagues and 72.8% was used as the high estimate based on the placebo plus SOC arm in the LIVE-AIR trial.

Results

Base Case and Scenario Analyses

In the base case and all scenario analyses, all specified clinical outcomes were improved with lenzilumab plus SOC over SOC alone (Table 1). In the base case, the NNT findings showed that every eighth patient treated with lenzilumab plus SOC rather than SOC alone avoided IMV or death. Across the scenario analyses this NNT ranged from a low of 4 in the Black with CRP <150 mg/L subgroup up to 15 in the full LIVE-AIR mITT population. Lenzilumab also provided a benefit in terms of mortality, with a base case NNT of 14 to save one life and this ranged from 8 to 23 across the scenario analyses. The addition of lenzilumab to SOC compared with SOC alone also reduced ventilator use by 12.6% (ranging from 6.5% to 26.8%) and 3.33 IMV days were saved in the base case analysis (ranging from 1.85 up to 5.50 days). Finally, the time to recovery was improved with lenzilumab plus SOC, saving 2.40 bed days (ranging from 0.99 up
to 4.92 days) as well as reducing time in ICU by 2.73 ICU days (ranging from 1.21 up to 5.06 days).

In addition to improved clinical outcomes, an estimated cost savings of £1,162 per patient resulted from adding lenzilumab to SOC in the base case analysis (Table 2). Scenario analysis #1 (aged <85 years with CRP <150 mg/L, with remdesivir) also produced an estimated cost savings of £3,127 per patient. In scenario analysis #2 (full LIVE-AIR mITT population), addition of lenzilumab to SOC was estimated to result in an additional cost of £4,005 per patient over SOC alone. Scenario analysis #3 (Black patients with CRP <150 mg/L, with or without remdesivir) and scenario analysis #4 (Black patients from the full mITT population) estimated cost savings of £9,977 and £2,369 per patient, respectively.

The estimated clinical benefits and cost impact of adding lenzilumab to SOC at the cohort level are shown in Table 3. In the base case analysis, it was estimated that for a weekly cohort of 4,754 newly hospitalized patients, the addition of lenzilumab to SOC would result in 609 additional patients achieving SWOV, 599 IMV uses avoided, and 11,400 bed days, 12,978 ICU days, 15,831 IMV days, and 352 additional lives saved. Additionally, in this weekly cohort, lenzilumab plus SOC produced an estimated cost savings of £5,524,952 compared to SOC alone. At the cohort level the scenario analyses also resulted in estimated cost savings ranging from £606,442 (scenario #4) to £5,604,188 (scenario #1), with the exception of scenario #2 (full LIVE-AIR mITT population) which produced an estimated £27,304,581 in additional costs.

**Sensitivity Analyses**

Overall, the economic impact of the sensitivity analyses was variable relative to the base case results, with adjustments to the inputs for hospital resources costs having the greatest impact on the estimated results. The findings of the sensitivity analyses are summarized in Table 4.

Varying the hospital resource costs resulted in an additional cost of £1,161 per patient with lower (-25%) resource use costs and cost savings of £3,485 per patient with higher (+25%) resource use costs, a decrease and increase in cost savings of 200%, relative to the base case.

Varying the patient distribution in the IMV and ICU level of care for the lenzilumab plus SOC arm
resulted in a 125% change in cost savings relative to the base case; reducing the patients in the IMV and ICU level of care by 25% increased the cost savings to £2,610 per patient, while increasing the patients in the IMV and ICU level of care by 25% resulted in an additional cost of £286 per patient. Altering the lenzilumab drug costs produced cost savings of £2,987 per patient with lower drug costs (−25%) and additional costs of £432 per patient with higher drug costs (+10%), an 157% increase and 63% decrease in cost savings, respectively, relative to the base case, respectively. Finally, a higher use of remdesivir in the SOC arm resulted in cost savings of £1,904 per patient, an increase of 64% relative to the base. Conversely, a lower use of remdesivir in the SOC arm decreased the cost savings to £718 per patient, a reduction of 38%.

**Discussion**

The present analysis evaluated the clinical and economic benefits of adding lenzilumab to SOC for the treatment of COVID-19 pneumonia from the NHS England perspective. The overall objective was to provide evidence to healthcare payers that may support the use of lenzilumab as a treatment option for this condition that urgently requires new efficacious therapies.

In the base case and all scenario analyses, treatment with lenzilumab plus SOC improved all specified clinical outcomes over SOC alone and resulted in a greater number of patients achieving SWOV and avoiding IMV use, as well as additional lives, bed days, ICU days, and IMV days saved. In the scenario analyses, the relative clinical benefits were smaller in the broader full mITT population scenario but greater in the narrower subgroup populations (ie, aged <85 years with CRP <150 mg/L receiving remdesivir and Black with CRP <150 mg/L, with or without remdesivir) compared to the base case.

Of the clinical outcomes assessed, SWOV is an important outcome for patients with COVID-19 from the NHS England perspective, as the average length of a patient’s hospital stay is greatly reduced by avoiding IMV. Notably, the average time to recovery for patients with IMV was more than double that of patients without IMV for all five analysis populations explored from the LIVE-AIR trial. In the base case analysis, addition of lenzilumab to SOC resulted in a 12.6% absolute reduction in the probability of requiring IMV compared with SOC alone among patients.
aged <85 years with CRP <150 mg/L. As observed in the LIVE-AIR trial, the estimates for failure
to achieve SWOV were similar between patients with CRP <150 mg/L regardless of age and
patients aged <85 years with CRP <150 mg/L (hazard ratio [95% confidence interval] of 2.54
[1.46-4.41] and 3.04 [1.68-5.51], respectively). These results suggest that the clinical benefits
observed in the present base case analysis would also likely be generalizable to a broader
population of patients with CRP <150 mg/L, irrespective of age.

In the base case analysis, lenzilumab was associated with per-patient cost savings from
the NHS England perspective. Although there were increases in drug acquisition and
administration costs associated with the addition of lenzilumab to SOC compared with SOC
alone, these additional costs were offset by the reduced costs for hospital resource use among
patients treated with lenzilumab. This resulted in a net per-patient cost savings of £1,162, and an
estimated total savings of £5,524,952 for a weekly cohort of 4,754 newly hospitalized patients
with CRP <150 mg/L and aged <85 years. Results from the sensitivity analyses suggested that
the variable with the greatest impact on the estimated cost savings of adding lenzilumab to SOC
versus SOC alone was hospital resource costs (±25%), resulting in a change of 200% from the
base case analysis. By comparison, varying patient distributions to different levels of care
(±25%), lenzilumab drug costs (+10% and −25%) and using different assumptions for remdesivir
use in the SOC alone arm (high estimate of 72.8%, low estimate of 16.7%) had less of an impact
on the cost savings associated with adding lenzilumab to SOC in the base case analysis.

In addition to the clinical benefits observed in the various populations examined, the
results show that adding lenzilumab to SOC for a narrower group of patients with baseline
CRP <150 mg/L, aged <85 years, and receiving remdesivir may also provide economic benefits
for UK hospitals, with a net per-patient cost savings of £3,127. However, in a broader population
of patients with COVID-19 pneumonia without consideration of CRP criteria or age, adding
lenzilumab to SOC had additional per-patient costs of £4,005, suggesting that there is greater
economic value in providing lenzilumab to a more targeted population.

Evidence suggests that CRP levels at the time of admission have a positive correlation
with disease severity and are associated with adverse clinical outcomes in patients hospitalized
with COVID-19. Furthermore, one of the strongest independent predictors of critical illness is CRP levels >100 mg/L at the time of admission, with patients having CRP levels >150 mg/L considered to be high risk for escalation of respiratory support (i.e., need for non-invasive ventilation or intubation) or death. Given that in patients aged <85 years with CRP levels <150 mg/L, irrespective of remdesivir use, lenzilumab produced favorable clinical outcomes and cost savings, it appears that using lenzilumab as an early intervention would be most effective and provide the best economic value. As testing for CRP levels is accessible and inexpensive in the UK hospital setting and has previously been recommended by the National Institute for Health and Care Excellence (NICE) as an option to inform the diagnosis and treatment of pneumonia in adults, it may be a valuable and feasible approach to identify hospitalized COVID-19 patients who may benefit most from lenzilumab treatment.

Clinical trials frequently underrepresent the Black population, despite this population being disproportionately affected by COVID-19. Consequently, there is limited evidence across racial populations regarding differences in disease severity, outcomes, and treatments. An exploratory analysis of the LIVE-AIR trial revealed that Black and African American patients, particularly those with a CRP level <150 mg/L, demonstrated the greatest response to treatment with lenzilumab. In the current analysis, the use of lenzilumab in Black patients with CRP <150 mg/L resulted in cost savings of £9,977 per patient, and a cost savings of £2,369 per patient when all Black patients were assessed. Assuming the Black and African American subgroup of LIVE-AIR are representative of potential outcomes in the Black African and Black Caribbean persons in the UK, these findings may be significant since this demographic is disproportionately affected by COVID-19, with an increased rate of death.

As with extrapolation of any clinical trial results, this study had several limitations. The analysis used data from the LIVE-AIR Phase 3 clinical trial that may have been subject to selection bias and that was predominantly conducted in US hospitals. Consequently, the findings from the trial may not be fully generalizable to a UK population and/or UK hospital setting based on potential differences in treatment patterns (e.g., length of hospital stay) for hospitalized patients with COVID-19 between the US and UK. It should also be noted that the LIVE-AIR trial was
conducted earlier in the pandemic and thus, prior to vaccinations and the emergence of new COVID-19 variants, both of which have been reported to affect hospital length of stay.\textsuperscript{11,63,64} As a result, time to recovery inputs derived from the clinical trial may differ from current real-world values. However, it is anticipated that the ongoing ACTIV-5/BET-B trial, which has completed the enrollment of over 400 patients in the primary analysis population, will provide data on the use of lenzilumab for hospitalized patients infected with different COVID-19 variants and with differing vaccination statuses.\textsuperscript{46,47} Additionally, the Black subgroups from the LIVE-AIR trial that were assessed in the per-patient calculator were limited by small sample sizes and will require further validation using the results from the upcoming ACTIV-5/BET-B trial. Consideration should also be given to the fact that the current analyses were conducted \textit{ex ante} and therefore, were conducted prior to regulatory approval of lenzilumab. Notably, a Conditional Marketing Authorisation (CMA) request for lenzilumab was submitted to the Medicines and Healthcare products Regulatory Agency (MHRA) on June 11, 2021 and is currently under review. Although the US Food and Drug Administration (FDA) (September 9, 2021) initially declined the request for emergency use authorization (EUA) of lenzilumab for the treatment of newly hospitalized COVID-19 patients based on the LIVE-AIR trial data, concluding further clinical data are needed, the FDA has invited Humanigen to submit any supplemental data as they become available.\textsuperscript{65} It is anticipated that the ongoing ACTIV-5/BET-B trial may provide additional efficacy and safety data sufficient to further support the use of lenzilumab for the treatment of hospitalized COVID-19 patients with a CRP <150 mg/L.\textsuperscript{46,47}

Although approximately 83.9\% and 64.3\% of individuals $\geq$12 years of age in the UK are now double and triple vaccinated, respectively, as of January 25, 2022,\textsuperscript{9} there remains an ongoing need for effective treatments for patients hospitalized with COVID-19 with the emergence of new variants.\textsuperscript{66} As per the NICE COVID-19 Treatment Guidelines, the current mainstays of care for hospitalized patients include remdesivir, corticosteroids, or both, casirivimab with imdevimab, and tocilizumab.\textsuperscript{67} However, these therapies may have a greater impact early in the disease course (remdesivir)\textsuperscript{68} or in patients with advanced disease (corticosteroids and tocilizumab).\textsuperscript{69,70} Therefore, effective treatment options are limited for hospitalized and hypoxic
patients with COVID-19 pneumonia, particularly early in the disease process to prevent ICU admission, IMV, and/or death. Lenzilumab is a particularly promising therapeutic as it addresses an unmet need for treatment options that prevent the progression to IMV and/or death in hospitalized patients. Additionally, the mechanism of action of lenzilumab functions by binding and neutralizing GM-CSF, which is produced in response to COVID-19 infection. Therefore, as was reported in the COVID-19 Therapeutics Strategy published by the European Commission, its efficacy is not anticipated to be affected by the new COVID-19 variants, including Omicron.\textsuperscript{38}

**Conclusions**

Overall, the findings from this analysis support the clinical benefits for SWOV, ventilator use, time to recovery, mortality, time in ICU, and time on IMV, as well as an economic benefit from the NHS England perspective associated with adding lenzilumab to SOC for patients with COVID-19 pneumonia. Lenzilumab provides clinical benefits to a broad population of patients with characteristics similar to the full mITT study cohort from the LIVE-AIR trial. Importantly, when used in patients aged <85 years with CRP <150 mg/L, lenzilumab appears to be particularly effective and is estimated to result in cost savings to the UK hospitals. Lenzilumab treatment in the Black population also resulted in clinical benefits and cost savings. As Black persons are hyper-vulnerable to COVID-19,\textsuperscript{42} this is a critical finding. Further clinical benefits and cost savings were observed with concomitant use of remdesivir with lenzilumab. These results support the use of lenzilumab as a standard treatment option for COVID-19 pneumonia and may help with its consideration for adoption in the hospital setting by hospital formulary decisions makers should an EUA or full approval through a Biologics License Application be granted.

**Abbreviations**

AE, adverse event; CMA, Conditional Marketing Authorisation; COVID-19, Coronavirus Disease 2019; CPI, consumer price inflation; CRP, C-reactive protein; EUA, emergency use authorization; EUR, euros; FDA, Food and Drug Administration; GBP, pound sterling; GM-CSF, granulocyte-macrophage colony-stimulating factor; ICU, intensive care unit; IL-6, interleukin-6; IMV, invasive
mechanical ventilation; MHRA, Medicines and Healthcare products Regulatory Agency; mITT, modified intent-to-treat; NHS, National Health Service; NICE, National Institute for Health and Care Excellence; NNT, number needed to treat; ONS, Office of National Statistics; SOC, standard of care; SpO₂, oxygen saturation; SWOV, survival without ventilation; UK, United Kingdom; US, United States.

**Ethics Approval and Informed Consent**

The current budget impact model did not require IRB oversight or approval. The LIVE-AIR trial on which the clinical efficacy was based was conducted in accordance with the Good Clinical Practice guidelines of the International Council for Harmonization E6 and the principles of the Declaration of Helsinki. The protocol was approved by Advarra, the central institutional review board. The ID number was Pro00043147. Additionally, local ethics committees at Mayo Clinic and the University of Southern California approved the protocol. Participants provided written informed consent.

**Acknowledgments**

The authors acknowledge Cameron Durant (Humanigen Inc.) and Avery Hughes (EVERSANA) for their specific contributions to this project.

**Author Contributions**

All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

**Funding**

This work was supported by Humanigen Inc.
Disclosure

AK, EJ, DC, MA are employees of Humanigen Inc. AZ, KT, ANP, RKT, MT are employees of EVERSANA which received funding from Humanigen Inc. to conduct this study.

References

1. Sarkodie SA, Owusu PA. Global assessment of environment, health and economic impact of the novel coronavirus (COVID-19). *Environ Dev Sustain.* 2020 Jun 5:5-11. doi: 10.1007/s10668-10020-00801-10662. Online ahead of print.

2. Kaye AD, Okeagu CN, Pham AD, et al. Economic impact of COVID-19 pandemic on healthcare facilities and systems: International perspectives. *Best Pract Res Clin Anaesthesiol.* 2021;35(3):293-306.

3. Nicola M, Alsafi Z, Sohrabi C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. *Int J Surg.* 2020;78:185-193.

4. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Available from: https://covid19.who.int/. Updated January 25, 2022. Accessed January 25, 2022.

5. Government of the United Kingdom. Cases in United Kingdom. Available from: https://coronavirus.data.gov.uk/details/cases. Updated January 25, 2022. Accessed January 25, 2022.

6. Government of the United Kingdom. Deaths in United Kingdom. Available from: https://coronavirus.data.gov.uk/details/deaths. Updated January 25, 2022. Accessed January 25, 2022.

7. Government of the United Kingdom. Patients Admitted to Hospital in United Kingdom. Available from: https://coronavirus.data.gov.uk/details/healthcare. Updated January 25, 2022. Accessed January 25, 2022.

8. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ.* 2020;369:m1985.
9. Government of the United Kingdom. Vaccinations in United Kingdom. Available from: https://coronavirus.data.gov.uk/details/vaccinations. Updated January 25, 2022.

10. Thakur V, Ratho RK. OMICRON (B.1.1.529): A new SARS-CoV-2 variant of concern mounting worldwide fear. J Med Virol. 2021 Dec 22. doi: 10.1002/jmv.27541. Online ahead of print.

11. United Kingdom Health Security Agency. SARS-CoV-2 Variants of Concern and Variants Under Investigation in England: Technical Briefing Updated on Hospitalisation and Vaccine Effectiveness for Omicron VOC-21-NOV-01 (B.1.1.529). Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1044481/Technical-Briefing-31-Dec-2021-Omicron_severity_update.pdf. Published 2021. Accessed January 5, 2022.

12. Callaway E, Ledford A. How Bad is Omicron? What Scientists Know So Far. Nature. 2021;600(7888):197-199.

13. Government of the United Kingdom. COVID-19 NHS Daily Situation Report. Available from: https://coronavirus.data.gov.uk/details/healthcare?areaType=nation&areaName=England. Updated January 25, 2022. Accessed January 25, 2022.

14. Rae M, Claxton G, Kurani N, McDermott D, Cox C. Potential costs of COVID-19 treatment for people with employer coverage. Available from: https://www.healthsystemtracker.org/brief/potential-costs-of-coronavirus-treatment-for-people-with-employer-coverage/. Published 2021. Accessed July 6, 2021.

15. Di Fusco M, Shea KM, Lin J, et al. Health outcomes and economic burden of hospitalized COVID-19 patients in the United States. J Med Econ. 2021;24(1):308-317.

16. Czernichow S, Bain SC, Capehorn M, et al. Costs of the COVID-19 pandemic associated with obesity in Europe: A health-care cost model. Clin Obes. 2021;11(2):e12442.
17. Sheinson D, Dang J, Shah A, Meng Y, Elsea D, Kowal S. A Cost-Effectiveness Framework for COVID-19 Treatments for Hospitalized Patients in the United States. *Adv Ther.* 2021;38(4):1811-1831.

18. Goletti D, Cantini F. Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled. *N Engl J Med.* 2021;384(9):867-869.

19. Liu CH, Lu CH, Wong SH, Lin LT. Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects. *Front Immunol.* 2020;11(3845):616595.

20. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 Cytokine Storm; What We Know So Far. *Front Immunol.* 2020;11:1446.

21. Lang FM, Lee KM, Teijaro JR, Becher B, Hamilton JA. GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches. *Nat Rev Immunol.* 2020;20(8):507-514.

22. Blot M, Bour JB, Quenot JP, et al. The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome. *J Transl Med.* 2020;18(1):457.

23. Temesgen Z, Burger CD, Baker J, et al. Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial. *Lancet Respir Med.* 2021 Dec 1;S2213-2600(21)00494-X. doi: 10.1016/S2213-2600(21)00494-X. Online ahead of print.

24. Hamilton JA. GM-CSF in inflammation. *J Exp Med.* 2020;217(1):e20190945.

25. Sproston NR, Ashworth JJ. Role of C-Reactive Protein at Sites of Inflammation and Infection. *Front Immunol.* 2018;9:754.

26. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood.* 2014;124(2):188-195.

27. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev Microbiol.* 2021;19(3):141-154.

28. Zhou Y, Fu B, Zheng X, et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. *Natl Sci Rev.* 2020;7(6):998-1002.
29. Thwaites RS, Sanchez Sevilla Uruchurtu A, Siggins MK, et al. Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. *Sci Immunol.* 2021;6(57).

30. Kox M, Waalders NJB, Kooistra EJ, Gerretsen J, Pickkers P. Cytokine Levels in Critically Ill Patients With COVID-19 and Other Conditions. *Jama.* 2020;324(15):1565-1567.

31. Hodges G, Pallisgaard J, Schjerning Olsen AM, et al. Association between biomarkers and COVID-19 severity and mortality: a nationwide Danish cohort study. *BMJ Open.* 2020;10(12):e041295.

32. Mueller AA, Tamura T, Crowley CP, et al. Inflammatory Biomarker Trends Predict Respiratory Decline in COVID-19 Patients. *Cell Rep Med.* 2020;1(8):100144.

33. Smilowitz NR, Kunichoff D, Garshick M, et al. C-reactive protein and clinical outcomes in patients with COVID-19. *Eur Heart J.* 2021;42(23):2270-2279.

34. Lavillegrand JR, Garnier M, Spaeth A, et al. Elevated plasma IL-6 and CRP levels are associated with adverse clinical outcomes and death in critically ill SARS-CoV-2 patients: inflammatory response of SARS-CoV-2 patients. *Ann Intensive Care.* 2021;11(1):9.

35. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. *BMJ.* 2020;369:m1966.

36. Luo X, Zhou W, Yan X, et al. Prognostic Value of C-Reactive Protein in Patients With Coronavirus 2019. *Clin Infect Dis.* 2020;71(16):2174-2179.

37. Ali N. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19. *J Med Virol.* 2020;92(11):2409-2411.

38. European Commission. European Health Union: Commission Establishes Portfolio of 10 Most Promising Treatments for COVID-19. Available from: [https://ec.europa.eu/commission/presscorner/detail/en/IP_21_5366](https://ec.europa.eu/commission/presscorner/detail/en/IP_21_5366). Published 2021. Accessed November 2, 2021.

39. Temesgen Z, Burger CD, Baker J, et al. Lenzilumab Efficacy and Safety in Newly Hospitalized Covid-19 Subjects: Results from the Live-Air Phase 3 Randomized Double-
Blind Placebo-Controlled Trial. *medRxiv.* 2021. doi: https://doi.org/10.1101/2021.05.01.21256470.

Temesgen Z, Kelley CF, Cerasoli F, et al. Early Lenzilumab Treatment of COVID-19 Patients Using C-Reactive Protein as a Biomarker Improves Efficacy: Results From the Phase 3 'LIVE-AIR' Trial. *medRxiv.* 2022. doi: https://doi.org/10.1101/2021.12.30.21267140.

Humanigen. Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and African-American COVID-19 Patients. Available from: https://ir.humanigen.com/English/news/news-details/2021/Lenzilumab-TreatmentMay-Provide-Enhanced-Likelihood-of-Survival-Without-Ventilation-in-Hospitalized-Black-and-African-American-COVID-19-Patients/default.aspx. Published 2021. Accessed September 24, 2021.

Office for National Statistics. Updating ethnic contrasts in deaths involving the coronavirus (COVID-19), England: 24 January 2020 to 31 March 2021. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/updatingethniccontrastsindeathsinvolvingthecoronaviruscovid19englandandwales/24january2020to31march2021. Published 2021. Accessed October 4, 2021.

Kadambari S, Vanderslott S. Lessons about COVID-19 vaccine hesitancy among minority ethnic people in the UK. *Lancet Infect Dis.* 2021;21(9):1204-1206.

Razai MS, Kankam HKN, Majeed A, Esmail A, Williams DR. Mitigating ethnic disparities in covid-19 and beyond. *BMJ.* 2021;372:m4921.

Kilcoyne A, Jordan E, Zhou A, et al. Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective. *Journal of Medical Economics.* 2022 Jan 17:1-21. doi: 10.1080/13696998.13692022.12030148.

Humanigen. ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04583969. NLM identifier:
47. Humanigen. Humanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved. Available from: https://ir.humanigen.com/English/news/news-details/2022/Humanigen-Announces-Target-Enrollment-in-Phase-23-ACTIV-5BET-B-Trial-of-Lenzilumab-for-the-Treatment-of-COVID-19-has-Been-Achieved/default.aspx. Published 2022. Accessed January 6, 2022.

48. Arch BN, Kovacs D, Scott JT, et al. Evaluation of the effectiveness of remdesivir in treating severe COVID-19 using data from the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, national cohort study. medRxiv. 2021. doi: https://doi.org/10.1101/2021.06.18.21259072.

49. Humanigen. Market research with chest physicians, infection control and intensive care specialists (N=82). Data on file. 2021.

50. Humanigen. Additional data analyses for LIVE-AIR Phase 3 randomized double-blind placebo-controlled trial. Data on file. 2021.

51. National Health Service Digital. Hospital admitted patient care and adult critical care activity 2020-21. Available from: https://digital.nhs.uk/data-and-information/publications/statistical/hospital-admitted-patient-care-activity/2020-21. Published 2021. Accessed January 10, 2022.

52. Office for National Statistics. Consumer price inflation time series; CPI INDEX 06: HEALTH. Available from: https://www.ons.gov.uk/economy/inflationandpriceindices/datasets/consumerpriceindices. Updated October 2021. Accessed January 12, 2022.

53. Humanigen. Lenzilumab drug cost. Data on file. 2022.

54. Specialist Pharmacy Service. Remdesivir. Available from: https://www.sps.nhs.uk/medicines/remdesivir/. Published 2020. Accessed July 15, 2021.

55. National Health Service. Interim clinical commissioning policy: Remdesivir for patients hospitalised with COVID-19 (adults and children 12 years and older). Available from:
56. Burcombe R, Chan S, Simcock R, Samanta K, Percival F, Barrett-Lee P. Subcutaneous Trastuzumab (Herceptin): A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer. *Advances in Breast Cancer Research*. 2013;02(04):133-140.

57. National Institute for Health and Care Excellence. Ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) [ID1530] committee papers. Available from: [https://www.nice.org.uk/guidance/ta710/documents/committee-papers-2](https://www.nice.org.uk/guidance/ta710/documents/committee-papers-2). Published 2020. Accessed July 20, 2021.

58. Lambert A. USP 797: A breakdown of low, medium and high compounding risks. Available from: [https://www.wolterskluwer.com/en/expert-insights/usp-797-a-breakdown-of-low-medium-and-high-risks](https://www.wolterskluwer.com/en/expert-insights/usp-797-a-breakdown-of-low-medium-and-high-risks). Published 2021. Accessed January 12, 2022.

59. Hazard D, Kaier K, von Cube M, et al. Joint analysis of duration of ventilation, length of intensive care, and mortality of COVID-19 patients: a multistate approach. *BMC Med Res Methodol.* 2020;20(1):206.

60. Manson JJ, Crooks C, Naja M, et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. *Lancet Rheumatol.* 2020;2(10):e594-e602.

61. Holmes EAF, Harris SD, Hughes A, Craine N, Hughes DA. Cost-Effectiveness Analysis of the Use of Point-of-Care C-Reactive Protein Testing to Reduce Antibiotic Prescribing in Primary Care. *Antibiotics (Basel).* 2018;7(4):106.

62. Chastain DB, Osae SP, Henao-Martinez AF, Franco-Paredes C, Chastain JS, Young HN. Racial Disproportionality in Covid Clinical Trials. *N Engl J Med.* 2020;383(9):e59.

63. Vekaria B, Overton C, Wisniowski A, et al. Hospital length of stay for COVID-19 patients: Data-driven methods for forward planning. *BMC Infect Dis.* 2021;21(1):700.
64. Imperial College COVID-19 Response Team. Report 50: Hospitalisation risk of Omicron cases in England. Available from: https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2021-12-22-COVID19-Report-50.pdf. Published 2021. Accessed January 17, 2022.

65. Humanigen. FDA has declined Humanigen’s Emergency Use Authorization (EUA) Request for Lenzilumab in Hospitalized COVID-19 Patients. Available from: https://ir.humanigen.com/English/news/news-details/2021/FDA-has-declined-Humanigens-Emergency-Use-Authorization-EUA-Request-for-Lenzilumab-in-Hospitalized-COVID-19-Patients/default.aspx. Published 2021. Accessed September 24, 2021.

66. Government of the United Kingdom. Daily Update: UK Summary. Available from: https://coronavirus.data.gov.uk/. Updated January 25, 2022. Accessed January 25, 2022.

67. National Institute for Health and Care Excellence. COVID-19 rapid guideline: Managing COVID-19. Available from: https://www.nice.org.uk/guidance/ng191/resources/covid19-rapid-guideline-managing-covid19-pdf-51035553326. Updated December 16, 2021. Accessed January 6, 2022.

68. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39(5):405-407.

69. Recovery Collaborative Group, Horby P, Lim WS, et al. Supplemental to: Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693-704.

70. Food and Drug Administration. Frequently Asked Questions on the Emergency Use Authorization for Actemra (Tocilizumab) for Treatment of COVID-19. Available from: https://www.fda.gov/media/150345/download#:~:text=The%20EUA%20authorizes%20Actemra%20tocilizumab%2C%20oxygen%2C%20non%2Dinvasive%2Dor%2Dinvasive. Published 2021. Accessed October 4, 2021.
Table 1 Estimated clinical benefits of lenzilumab plus SOC over SOC alone per treated patient.

| Scenario | Base case: aged <85 years with CRP <150 mg/L | Scenario #1: aged <85 years with CRP <150 mg/L, receiving remdesivir | Scenario #2: full LIVE-AIR mITT population | Scenario #3: Black with CRP <150 mg/L | Scenario #4: Black |
|----------|---------------------------------------------|-------------------------------------------------|----------------------------------------|---------------------------------|------------------|
| **Failure to achieve SWOV**<sup>a</sup> | | | | | |
| Lenzilumab plus SOC | 8.4% | 9.2% | 15.6% | 4.0% | 13.2% |
| SOC alone | 21.2% | 24.8% | 22.1% | 29.3% | 29.1% |
| NNT for one patient to achieve SWOV | 8 | 6 | 15 | 4 | 6 |
| **Ventilator use** | | | | | |
| Lenzilumab plus SOC | 8.2% | 8.9% | 15.3% | 4.0% | 13.2% |
| SOC alone | 20.8% | 24.4% | 21.8% | 30.8% | 30.3% |
| Reduced IMV use | 12.6% | 15.5% | 6.5% | 26.8% | 17.1% |
| **Mortality**<sup>a</sup> | | | | | |
| Lenzilumab plus SOC | 6.5% | 7.5% | 9.6% | 4.0% | 7.9% |
| SOC alone | 13.9% | 17.3% | 13.9% | 17.1% | 16.5% |
| NNT for one life saved | 14 | 10 | 23 | 8 | 12 |
|------------------------|----|----|----|---|----|
| **Time to recovery (days)** | | | | | |
| Lenzilumab plus SOC | 9.21 | 9.93 | 11.09 | 8.32 | 10.87 |
| SOC alone | 11.61 | 12.33 | 12.08 | 13.24 | 13.45 |
| Bed days saved | 2.40 | 2.40 | 0.99 | 4.92 | 2.58 |
| **Time in ICU (days)** | | | | | |
| Lenzilumab plus SOC | 3.48 | 3.79 | 5.40 | 1.48 | 4.68 |
| SOC alone | 6.21 | 6.76 | 6.61 | 6.54 | 7.06 |
| ICU days saved | 2.73 | 2.97 | 1.21 | 5.06 | 2.38 |
| **Time on IMV (days)** | | | | | |
| Lenzilumab plus SOC | 1.92 | 2.12 | 3.53 | 1.12 | 3.11 |
| SOC alone | 5.25 | 6.02 | 5.38 | 6.62 | 6.48 |
| IMV days saved | 3.33 | 3.90 | 1.85 | 5.50 | 3.37 |

**Note:**

These values were derived from Kaplan–Meier analysis.

**Abbreviations:** CRP, C-reactive protein; ICU, intensive care unit; IMV, invasive mechanical ventilation; mITT, modified intent-to-treat; NNT, number needed to treat; SOC, standard of care; SWOV, survival without ventilation.
Table 2  Estimated economic impact of lenzilumab plus SOC versus SOC alone per treated patient.

|                                      | Lenzilumab Acquisition Costs | Remdesivir Acquisition Costs | Drug Administration Costs | Hospital Resource Use Costs | Total Treatment Costs | Cost Difference\(^b\) |
|--------------------------------------|------------------------------|-------------------------------|---------------------------|--------------------------|----------------------|------------------------|
| **Base case: aged <85 years with CRP <150 mg/L** |                              |                               |                           |                          |                      |                        |
| Lenzilumab plus SOC                  | £7,300                       | £1,471                        | £155                      | £15,493                  | £24,419              | -£1,162                |
| SOC alone                            | £0                           | £769                          | £28                       | £24,784                  | £25,581              |                        |
| **Scenario #1: aged <85 years with CRP <150 mg/L, receiving remdesivir** |                              |                               |                           |                          |                      |                        |
| Lenzilumab plus SOC                  | £7,300                       | £2,040                        | £176                      | £16,611                  | £26,126              | -£3,127                |
| SOC alone                            | £0                           | £2,040                        | £74                       | £27,140                  | £29,254              |                        |
| **Scenario #2: full LIVE-AIR mITT population** |                              |                               |                           |                          |                      |                        |
| Lenzilumab plus SOC                  | £7,300                       | £1,471                        | £155                      | £21,824                  | £30,750              | £4,005                 |
| SOC alone                            | £0                           | £987                          | £36                       | £25,721                  | £26,744              |                        |
| **Scenario #3: Black with CRP <150 mg/L** |                              |                               |                           |                          |                      |                        |
| Lenzilumab plus SOC                  | £7,300                       | £1,471                        | £155                      | £11,682                  | £20,608              | -£9,977                |
| SOC alone                            | £0                           | £769                          | £28                       | £29,788                  | £30,585              |                        |
| **Scenario #4: Black**               |                              |                               |                           |                          |                      |                        |

\(^a\) Acquisition costs include dosing, daily administration, and associated handling fees. Costs are in British pounds (£).
| Lenzilumab plus SOC | £7,300 | £1,471 | £155 | £20,436 | £29,362 | -£2,369 |
|---------------------|--------|--------|------|---------|---------|---------|
| SOC alone           | £0     | £987   | £36  | £30,708 | £31,731 |         |

**Note:**

a Additional details regarding the assumptions and calculations for remdesivir use can be found in the Drug Acquisitions Costs section and in the associated Supplementary Appendix.

b Negative numbers indicate a net cost savings with lenzilumab, whereas positive numbers indicate a net increase in per-patient costs with lenzilumab.

**Abbreviations:** CRP, C-reactive protein; mITT, modified intent-to-treat; SOC, standard of care.
Table 3 Estimated clinical benefits and economic impact of lenzilumab plus SOC over SOC alone for a weekly cohort of newly hospitalized patients with COVID-19 in England for different population subgroups.

| Populationa | Additional Patients Achieving SWOVb | IMV Uses Avoidedb | Additional Lives Savedb | Bed Days Savedb | ICU Days Savedb | IMV Days Savedb | Cost Difference Per Cohortc |
|-------------|-----------------------------------|-------------------|-------------------------|----------------|----------------|----------------|-----------------------------|
| Base case: aged <85 years with CRP <150 mg/L\textsuperscript{13,40,49,51} (n = 4,754) | 609 | 599 | 352 | 11,400 | 12,978 | 15,831 | £5,524,952 |
| Scenario #1: aged <85 years with CRP <150 mg/L, receiving remdesivir\textsuperscript{13,40,49,51} (n = 1,792) | 280 | 277 | 176 | 4,307 | 5,322 | 6,989 | £5,604,188 |
| Scenario #2: full LIVE-AIR mITT population\textsuperscript{13,49} (n = 6,817) | 443 | 443 | 293 | 6,726 | 8,249 | 12,611 | £27,304,581 |
Scenario #3: Black with CRP <150 mg/L\textsuperscript{13,40,49,51} (n = 200)

|     | 51 | 54 | 26 | 984 | 1,012 | 1,100 | -£1,995,391 |

Scenario #4: Black\textsuperscript{13,49,51} (n = 256)

|     | 41 | 44 | 22 | 661 | 609 | 863 | -£606,442 |

Notes:

\textsuperscript{a} Estimated cohort sizes were calculated using the total number of new COVID-19 hospital admissions in England over a one-week period (11,343; from January 17 to January 23, 2022),\textsuperscript{13} adjusted to the population of interest based on SpO\textsubscript{2} <94\% (60.1\%),\textsuperscript{49} CRP <150 mg/L (77.9\%),\textsuperscript{40} proportion <85 years (89.5\%),\textsuperscript{51} proportion receiving remdesivir for those with CRP <150 mg/L (37.7\%),\textsuperscript{49} and proportion Black (3.8\%),\textsuperscript{51} as appropriate.

\textsuperscript{b} Values represent the difference of adding lenzilumab to SOC compared with SOC alone based on analyses of the LIVE-AIR trial.\textsuperscript{50}

\textsuperscript{c} Negative numbers indicate a net cost savings with lenzilumab, whereas positive numbers indicate a net budget impact with lenzilumab.

Abbreviations: COVID-19, Coronavirus Disease 19; CRP, C-reactive protein; ICU, intensive care unit; IMV, invasive mechanical ventilation; mITT, modified intent-to-treat; SOC, standard of care; SWOV, survival without ventilation.
Table 4 Sensitivity analyses.

|                        | Base Case Values | Sensitivity Values | Sensitivity Analysis Results | Difference from Base Case |
|------------------------|------------------|-------------------|-----------------------------|---------------------------|
| **Hospital Resource Costs: +25%** |                  |                   |                             |                           |
| No ICU, no IMV         | £876             | £1,095            | -£3,485                     | 200% increase in cost savings |
| ICU, but no IMV        | £1,978           | £2,473            |                             |                           |
| IMV, but no ICU        | £2,043           | £2,554            |                             |                           |
| Both ICU and IMV       | £3,145           | £3,931            |                             |                           |
| **Hospital Resource Costs: -25%** |                  |                   |                             |                           |
| No ICU, no IMV         | £876             | £657              | £1,161                      | 200% decrease in cost savings |
| ICU, but no IMV        | £1,978           | £1,484            |                             |                           |
| IMV, but no ICU        | £2,043           | £1,532            |                             |                           |
| Both ICU and IMV       | £3,145           | £2,359            |                             |                           |
| **Patient distributions: +25% (IMV and ICU)** |                  |                   |                             |                           |
| No ICU, no IMV         | 72.3%            | 70.7%             | £286                        | 125% decrease in cost savings |
| ICU, but no IMV        | 19.5%            | 19.1%             |                             |                           |
| IMV, but no ICU        | 0.0%             | 0.0%              |                             |                           |
### Patient distributions: -25% (IMV and ICU)\(^b\)

|                      | 8.2% | 10.3% |
|----------------------|------|-------|
| No ICU, no IMV       | 72.3%| 73.9% |
| ICU, but no IMV      | 19.5%| 19.9% |
| IMV, but no ICU      | 0.0% | 0.0%  |
| Both ICU and IMV     | 8.2% | 6.2%  |

### Lenzilumab Drug Costs: +10\(^b\)

|                      | £7,300 | £8,030 | £432 | 63% decrease in cost savings |
|----------------------|--------|--------|------|----------------------------|
| Lenzilumab Drug Costs: -25\(^b\) | £7,300 | £5,475 | £2,987 | 157% increase in cost savings |

### Remdesivir Use (SOC arm): High\(^c\)

|                      | 37.7% | 72.8% | £1,904 | 64% increase in cost savings |
|----------------------|-------|-------|--------|----------------------------|

### Remdesivir Use (SOC arm): Low\(^d\)

|                      | 37.7% | 16.7% | £718  | 38% decrease in cost savings |

**Notes:**

- \(^a\) Negative numbers indicate a net cost savings with lenzilumab.
- \(^b\) Input values changed only for the lenzilumab plus SOC group.
- \(^c\) Source: Temesgen et al. (2021).\(^23\)
Abbreviations: ICU, intensive care unit; IMV, invasive mechanical ventilation; SOC, standard of care.
Figure 1 Cost calculator structure

| Lenzilumab + SOC | SOC Alone |
|------------------|----------|
| **Population**   |          |
| Newly hospitalized patients with COVID-19 pneumonia (choice of full eligible population or various subgroups) |

| Inputs |          |
|--------|----------|
| Lenzilumab and remdesivir drug acquisition and administration costs* | Remdesivir drug acquisition and administration costs* |
| Hospital resource rates and costs for lenzilumab + SOC | Hospital resource rates and costs for SOC alone |

| Results |          |
|---------|----------|
| Clinical outcomes with lenzilumab + SOC | Clinical outcomes with SOC alone |

* Net Clinical Benefits with Lenzilumab + SOC vs. SOC Alone
| Total costs of managing COVID-19 patients with lenzilumab + SOC | Total costs of managing COVID-19 patients with SOC alone |

* Budget Impact with Lenzilumab + SOC vs. SOC Alone

**Note:**

It was assumed that use of SOC drugs, other than remdesivir, would not be affected by the concomitant use of lenzilumab, resulting in no cost differences for SOC drugs between both groups. This assumption was supported by the balanced use of corticosteroids in both treatment arms of the LIVE-AIR trial.23

**Abbreviations:** COVID-19, Coronavirus Disease 19; SOC, standard of care.
Figure 2 Calculations of the weekly cohort size estimates

| Population                                                                 | Base Case: Aged <85 years with CRP <150 mg/L | Scenario #1: Aged <85 years with CRP <150 mg/L, receiving remdesivir | Scenario #2: Full LIVE-AIR mITT population | Scenario #3: Black with CRP <150 mg/L | Scenario #4: Black |
|----------------------------------------------------------------------------|---------------------------------------------|-------------------------------------------------|------------------------------------------|----------------------------------------|-------------------|
| Newly hospitalized with COVID-18                                            | n = 11,343                                  |                                                 |                                          |                                        |                   |
| SpO₂ ≤94%: 60.1%                                                          |                                             | n = 6,817                                       |                                          |                                        |                   |
| CRP <150 mg/L: 77.5%                                                       | n = 5,311                                   | n = 5,311                                       |                                          | n = 5,311                              |                   |
| Age <85 years: 89.5%                                                       | n = 4,754                                   | n = 4,754                                       |                                          |                                        |                   |
| Receiving remdesivir: 37.7%                                                |                                             |                                                 |                                          |                                        | n = 1,792         |
| Black patients: 3.8%                                                       |                                             |                                                 |                                          |                                        |                   |
| Final cohort size                                                          | n = 4,754                                   | n = 1,792                                       | n = 6,817                                | n = 200                                | n = 256           |
Notes:

a Estimated cohort sizes were calculated using the total number of new COVID-19 hospital admissions in England over a one-week period (11,343; from January 17 to January 23, 2022). Based on the physician survey, 60.1% of hospitalized patients have SpO$_2 \leq 94$% and it was assumed that 77.9% of this population has CRP <150 mg/L, as observed in the LIVE-AIR trial. For base case and scenario #1, it was assumed that 89.5% of the hospitalized population was <85 years and the subgroup receiving remdesivir was calculated using data from the physician survey which estimated 37.7%. Lastly, for scenarios #3 and #4, it was assumed that 3.8% of the patient were Black.

b Source: Government of the United Kingdom.

c Source: Humanigen. Data on file.

d Source: Temesgen et al. (2021).

e Source: National Health Service Digital.

Abbreviations: COVID-19, Coronavirus Disease 19; CRP, C-reactive protein; mITT, modified intent-to-treat; SpO$_2$, oxygen saturation.